## Marianne Gex-Fabry

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10775515/publications.pdf

Version: 2024-02-01

257450 243625 2,041 54 24 citations h-index papers

g-index 55 55 55 2580 docs citations times ranked citing authors all docs

44

#	Article	IF	CITATIONS
1	Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to Analgesics: A Retrospective Study. Journal of Personalized Medicine, 2020, 10, 198.	2.5	10
2	Tobacco craving and withdrawal symptoms in psychiatric patients during a motivational enhancement intervention based on a 26-hour smoking abstinence period. Tobacco Prevention and Cessation, 2019, 5, 22.	0.4	4
3	Measuring racing thoughts in healthy individuals: The Racing and Crowded Thoughts Questionnaire (RCTQ). Comprehensive Psychiatry, 2018, 82, 37-44.	3.1	13
4	Subjective Distress Associated with Adult ADHD: evaluation of a new self-report. ADHD Attention Deficit and Hyperactivity Disorders, 2018, 10, 77-86.	1.7	4
5	Phenotypic Assessment of Drug Metabolic Pathways and P-Glycoprotein in Patients Treated With Antidepressants in an Ambulatory Setting. Journal of Clinical Psychiatry, 2018, 79, 16m11387.	2.2	8
6	Self-Reported Long-Term Benefits of Mindfulness-Based Cognitive Therapy in Patients with Bipolar Disorder. Journal of Alternative and Complementary Medicine, 2017, 23, 534-540.	2.1	17
7	Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study. Pharmacological Research, 2017, 118, 104-110.	7.1	13
8	Maternal PTSD and corresponding neural activity mediate effects of child exposure to violence on child PTSD symptoms. PLoS ONE, 2017, 12, e0181066.	2.5	23
9	Group Psychoeducation for Relatives of Persons With Bipolar Disorder. Journal of Nervous and Mental Disease, 2015, 203, 730-734.	1.0	7
10	Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis. PLoS ONE, 2015, 10, e0127213.	2.5	24
11	Increased Reward-Related Behaviors during Sleep and Wakefulness in Sleepwalking and Idiopathic Nightmares. PLoS ONE, 2015, 10, e0134504.	2.5	15
12	Methylation of NR3C1 is related to maternal PTSD, parenting stress and maternal medial prefrontal cortical activity in response to child separation among mothers with histories of violence exposure. Frontiers in Psychology, 2015, 6, 690.	2.1	67
13	How do Maternal PTSD and Alexithymia Interact to Impact Maternal Behavior?. Child Psychiatry and Human Development, 2015, 46, 406-417.	1.9	55
14	Long-term mental health outcome in post-conflict settings: Similarities and differences between Kosovo and Rwanda. International Journal of Social Psychiatry, 2015, 61, 363-372.	3.1	19
15	Subjective Experience of Thought Overactivation in Mood Disorders: Beyond Racing and Crowded Thoughts. Psychopathology, 2014, 47, 174-184.	1.5	17
16	Screening for bipolar disorder in adolescents with the <scp>M</scp> ood <scp>D</scp> isorder <scp>Q</scp> uestionnaire – <scp>A</scp> dolescent version ( <scp>MDQ</scp> â€ <scp>A</scp> ) and the <scp>C</scp> hild <scp>B</scp> ipolar <scp>Q</scp> uestionnaire ( <scp>CBQ</scp> ). Microbial Biotechnology, 2013, 7, 270-277.	1.7	6
17	Drug-Induced Long QT in Adult Psychiatric Inpatients: The 5-Year Cross-Sectional ECG Screening Outcome in Psychiatry Study. American Journal of Psychiatry, 2013, 170, 1468-1476.	7.2	94
18	Use of healthcare services 8 years after the war in Kosovo: role of post-traumatic stress disorder and depression. European Journal of Public Health, 2012, 22, 638-643.	0.3	13

#	Article	IF	Citations
19	Mental and physical health in Rwanda 14Âyears after the genocide. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 1753-1761.	3.1	103
20	Long-term impact of the life goals group therapy program for bipolar patients. Journal of Affective Disorders, 2012, 136, 889-894.	4.1	11
21	Salivary cortisol profiles in patients remitted from recurrent depression: One-year follow-up of a mindfulness-based cognitive therapy trial. Journal of Psychiatric Research, 2012, 46, 80-86.	3.1	34
22	Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics, 2011, 12, 365-377.	1.3	49
23	Mental and physical health of Kosovar Albanians in their place of origin: a post-war 6-year follow-up study. Social Psychiatry and Psychiatric Epidemiology, 2011, 46, 953-963.	3.1	21
24	A multiparameter panel method for outcome prediction following aneurysmal subarachnoid hemorrhage. Intensive Care Medicine, 2010, 36, 107-115.	8.2	75
25	The cortisol awakening response in patients remitted from depression. Journal of Psychiatric Research, 2010, 44, 1199-1204.	3.1	24
26	Depression relapse prophylaxis with Mindfulness-Based Cognitive Therapy: Replication and extension in the Swiss health care system. Journal of Affective Disorders, 2010, 122, 224-231.	4.1	180
27	Performance of the Mood Disorder Questionnaire (MDQ) according to bipolar subtype and symptom severity. European Psychiatry, 2009, 24, 341-344.	0.2	23
28	CYP2D6 and ABCB1 Genetic Variability: Influence on Paroxetine Plasma Level and Therapeutic Response. Therapeutic Drug Monitoring, 2008, 30, 474-482.	2.0	116
29	Influence of ABCB1 Gene Polymorphisms and P-Glycoprotein Activity on Cyclosporine Pharmacokinetics in Peripheral Blood Mononuclear Cells in Healthy Volunteers. Drug Metabolism Letters, 2008, 2, 76-82.	0.8	29
30	Model-Based Analysis of Gd-BOPTA-Induced MR Signal Intensity Changes in Cirrhotic Rat Livers. Investigative Radiology, 2007, 42, 513-521.	6.2	17
31	Health status of returnees to Kosovo: Do living conditions during asylum make a difference?. Public Health, 2007, 121, 34-44.	2.9	22
32	Time course of response to paroxetine: Influence of plasma level. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 892-900.	4.8	15
33	Ubiquitin Fusion Degradation Protein 1 as a Blood Marker for the Early Diagnosis of Ischemic Stroke. Biomarker Insights, 2007, 2, 117727190700200.	2.5	10
34	Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke. Biomarker Insights, 2007, 2, 155-64.	2.5	13
35	Impact of the life goals group therapy program for bipolar patients: An open study. Journal of Affective Disorders, 2006, 93, 253-257.	4.1	27
36	Quantification of Gd-BOPTA Uptake and Biliary Excretion From Dynamic Magnetic Resonance Imaging in Rat Livers. Investigative Radiology, 2005, 40, 705-714.	6.2	21

#	Article	IF	Citations
37	Screening for bipolar disorders using a French version of the Mood Disorder Questionnaire (MDQ). Journal of Affective Disorders, 2005, 88, 103-108.	4.1	88
38	Time course of clinical response to venlafaxine: relevance of plasma level and chirality. European Journal of Clinical Pharmacology, 2004, 59, 883-891.	1.9	52
39	Determinants of Postconflict Symptoms in Albanian Kosovars. Journal of Nervous and Mental Disease, 2004, 192, 664-671.	1.0	74
40	Gd-BOPTA Transport Into Rat Hepatocytes: Pharmacokinetic Analysis of Dynamic Magnetic Resonance Images Using a Hollow-Fiber Bioreactor. Investigative Radiology, 2004, 39, 506-515.	6.2	26
41	Therapeutic Drug Monitoring of Olanzapine: The Combined Effect of Age, Gender, Smoking, and Comedication. Therapeutic Drug Monitoring, 2003, 25, 46-53.	2.0	145
42	A Retrospective Comparison of Inpatients with Mixed and Pure Depression. Psychopathology, 2003, 36, 292-298.	1.5	25
43	Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. European Journal of Clinical Pharmacology, 2002, 58, 323-331.	1.9	25
44	Therapeutic Drug Monitoring Databases for Postmarketing Surveillance of Drug-Drug Interactions. Drug Safety, 2001, 24, 947-959.	3.2	18
45	Population Pharmacokinetics of Clomipramine, Desmethylclomipramine, and Hydroxylated Metabolites in Patients With Depression Receiving Chronic Treatment: Model Evaluation. Therapeutic Drug Monitoring, 2000, 22, 701-711.	2.0	12
46	Development of validated stereoselective methods for methadone determination in clinical samples., 1999, 11, 487-494.		31
47	Therapeutic Drug Monitoring of Risperidone Using a New, Rapid HPLC Method: Reappraisal of Interindividual Variability Factors. Therapeutic Drug Monitoring, 1999, 21, 105-115.	2.0	114
48	Therapeutic Drug Monitoring Databases for Postmarketing Surveillance of Drug-Drug Interactions. Therapeutic Drug Monitoring, 1997, 19, 1-10.	2.0	32
49	Potential of Concentration Monitoring Data for a Short Half-Life Drug. Therapeutic Drug Monitoring, 1995, 17, 39-46.	2.0	25
50	Implications for the design and interpretation of Phase III clinical trials. , 1994, , 201-217.		2
51	Clinical Pharmacokinetics of Clomipramine. Clinical Pharmacokinetics, 1991, 20, 447-462.	3.5	98
52	Clomipramine Metabolism. Clinical Pharmacokinetics, 1990, 19, 241-255.	3.5	72
53	Modelling in Preclinical and Clinical Drug Development. , 0, , 15-29.		2
54	Dealing with Metabolic Variability during Drug Development. , 0, , 313-331.		O